A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry

Ver/ abrir
Use este enlace para citar
http://hdl.handle.net/2183/29406
A non ser que se indique outra cousa, a licenza do ítem descríbese como Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0)
Coleccións
- Investigación (FCS) [1293]
Metadatos
Mostrar o rexistro completo do ítemTítulo
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term RegistryAutor(es)
Data
2021-12-27Cita bibliográfica
Kapłon-Cieślicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Ruschitzka F, Hage C, Drożdż J, Seferovic P, Rosano GMC, Piepoli M, Mebazaa A, McDonagh T, Lainscak M, Savarese G, Ferrari R, Maggioni AP, Lund LH; on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2022 Feb;24(2):335-350.
Resumo
[Abstract] Aims: To perform a comprehensive characterization of acute heart failure (AHF) with preserved (HFpEF), versus mildly reduced (HFmrEF) versus reduced ejection fraction (HFrEF).
Methods and results: Of 5951 participants in the ESC HF Long-Term Registry hospitalized for AHF (acute coronary syndromes excluded), 29% had HFpEF, 18% HFmrEF, and 53% HFrEF. Hospitalization reasons were most commonly atrial fibrillation (more in HFmrEF and HFpEF), followed by ischaemia (HFmrEF), infection (HFmrEF and HFpEF), worsening renal function (HFrEF), and uncontrolled hypertension (HFmrEF and HFpEF). Hospitalization characteristics included lower blood pressure, more oedema and higher natriuretic peptides with lower ejection fraction, similar pulmonary congestion, more mitral regurgitation in HFrEF and HFmrEF and more tricuspid regurgitation in HFrEF. In-hospital mortality was 3.4% in HFrEF, 2.1% in HFmrEF and 2.2% in HFpEF. Intravenous diuretic (∼80%) and nitrate (∼15%) use was similar but inotrope use greater in HFrEF (16%, vs. HFmrEF 7.4% vs. HFpEF 5.3%). Weight loss and estimated glomerular filtration rate improvement were greater in HFrEF, whereas reduction in natriuretic peptides was similar. Over 1 year post-discharge, events per 100 patient-years (95% confidence interval) in HFrEF versus HFmrEF versus HFpEF were: all-cause death 22 (20-24) versus 17 (14-20) versus 17 (15-20); cardiovascular (CV) death 12 (10-13) versus 8.6 (6.6-11) versus 8.4 (6.9-10); non-CV death 2.4 (1.8-3.1) versus 3.3 (2.1-4.8) versus 4.5 (3.5-5.9); all-cause hospitalization 48 (45-51) versus 35 (31-40) versus 42 (39-46); HF hospitalization 29 (27-32) versus 19 (16-22) versus 17 (15-20); and non-CV hospitalization 7.7 (6.6-8.9) versus 9.6 (7.5-12) versus 15 (13-17).
Conclusion: In AHF, HFrEF is more severe and has greater in-hospital mortality. Post-discharge, HFrEF has greater CV risk, HFpEF greater non-CV risk, and HFmrEF lower overall risk.
Palabras chave
Heart failure with mid-range ejection fraction
Heart failure with mildly reduced ejection fraction
Heart failure with preserved ejection fraction
Hospitalization
Prognosis
Treatment
Heart failure with mildly reduced ejection fraction
Heart failure with preserved ejection fraction
Hospitalization
Prognosis
Treatment
Versión do editor
Dereitos
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0)
ISSN
1388-9842
Ítems relacionados
Mostrando ítems relacionados por Título, autor ou materia.
-
Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry
Bonapace, Stefano; Rossi, Andrea; Laroche, Cécile; Crespo-Leiro, María Generosa; Piepoli, Massimo F.; Coats, Andrew J. S.; Dahlström, Ulf; Malek, Filip; Macarie, Cezar; Temporelli, Pier Luigi; Maggioni, Aldo P.; Tavazzi, Luigi (Willey Online Library, 2019-12-09)[Abstract] Aims To investigate the still uncertain independent prognostic impact of pulse pressure (PP) in acute heart failure (HF), in particular across the left ventricular ejection fraction (EF) phenotypes, and the ... -
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use
Papp, Zoltán; Álvarez, Julián; Bettex, Dominique; Bouchez, Stefan; Brito, Dulce; Černý, Vladimir; Comín-Colet, Josep; Crespo-Leiro, María Generosa; Delgado Jiménez, Juan Francisco; Édes, István; Eremenko, Alexander; Farmakis, Dimitrios; Fedele, Francesco; Fonseca, Cândida; Fruhwald, Sonja; Girardis, Massimo; Guarracino, Fabio; Harjola, Veli-Pekka; Heringlake, Matthias; Herpain, Antoine; Heunks, Leo; Husebye, Tryggve; Ivancan, Višnja; Karason, Kristjan; Kaul, Sundeep; Kivikko, Matti; Kubica, Janek; Masip, Josep; Matskeplishvili, Simon; Mebazaa, Alexandre; Nieminen, Markku S.; Oliva, Fabrizio; Papp, Julius G.; Parissis, John; Parkhomenko, Alexander; Põder, Pentti; Pölzl, Gerhard; Reinecke, Alexander; Ricksten, Sven-Erik; Riha, Hynek; Rudiger, Alain; Sarapohja, Toni; Schwinger, Robert H. G.; Toller, Wolfgang; Tritapepe, Luigi; Tschöpe, Carsten; Wikström, Gerhard; Lewinski, Dirk von; Vrtovec, Bojan; Pollesello, Piero; Agostoni, Piergiuseppe (Wolters Kluwer, 2020-07)[Abstract] Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart ... -
Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction: a review
Pascual-Figal, Domingo; Bayes-Genis, A.; Beltrán-Troncoso, Paola; Caravaca-Pérez, Pedro; Conde-Martel, Alicia; Crespo-Leiro, María Generosa; Delgado Jiménez, Juan Francisco; Díez, Javier; Formiga, Francesc; Manito, Nicolás (Frontiers, 2021-11-11)[Abstract] Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high prevalence, it is a ...